For relapsed or resistant DLBCL, odronextamab produced positive results.

Published Date: 22 Dec 2023

Experts are unsure of how it would fit in with the currently accepted bispecifics, though.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.

2.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

3.

Cancer diagnosis does not spur improvements to survivors' diets or eating habits

4.

According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.

5.

A garden can save your life


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot